SailajaKamarajuMD

Oncology • West Bend, WI

Assistant Professor, Medicine, Medical College of Wisconsin

Join to view full profile

Dr. Kamaraju is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kamaraju's full profile

Already have an account?

Office
1110 Oak St
Alyce Elmore Kraemer Cancer Care Center
West Bend, WI 53095
Phone+1 262-334-8484

Fax+1 414-805-4944

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
Hennepin HealthcareResidency, Internal Medicine, 1996 - 1999
University of Arizona College of Medicine-Tucson (South Campus)Internship, Internal Medicine, 1995 - 1996
Guntur Medical College NTRClass of 1993

Certifications & Licensure

WI State Medical License 2002 - 2025
TX State Medical License 2008 - 2015
MN State Medical License 1998 - 2005
IL State Medical License 2002 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Start of enrollment: 2021 Oct 05
Terminated
Phase 2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer Start of enrollment: 2024 Mar 15
Not yet recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Equitable community-based participatory research engagement with communities of color drives All of Us Wisconsin genomic research priorities.
Suma K Thareja, Xin Yang, Paramita Basak Upama, Aziz Abdullah, Shary Pérez Torres
Journal of the American Medical Informatics Association. 2024-12-01
The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.
Joan M Neuner, Melinda Stolley, Sailaja Kamaraju, Jacob Tiegs, Rodney Sparapani
Breast Cancer Research and Treatment. 2024-11-26
Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer.
Kun Fang, Aigbe G Ohihoin, Tianxiang Liu, Lavanya Choppavarapu, Bakhtiyor Nosirov
Genome Medicine. 2024-11-18

Press Mentions

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast CancerDecember 11th, 2024
Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member